According to the Zhitong Finance App, Yeju Medical (06929.HK) announced that the key clinical trial (OM-0031) conducted in Japan has completed the first patient enrollment. This trial will evaluate coronary paclitaxel drug-coated balloons (“drug-coated balloons”, DCB) independently developed by the Group, marking an important step in consolidating the Group's leading position in the Japanese interventional cardiology market with a diversified product portfolio.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.